Trenton, NJ (March 17, 2016) – BioNJ President and CEO Debbie Hart released the following statement regarding the proposed rule by the Centers for Medicare and Medicaid Services to test new Medicare Part B prescription drug models in an attempt to “improve quality of care and deliver better value for Medicare beneficiaries.”
“BioNJ opposes the proposed Centers for Medicaid and Medicare Services (CMS) Rule Change to Medicare Part B which would change the reimbursement model for essential, often life-saving drugs that are administered to patients in physician offices. Part B covers clinical research, ambulance services, mental health inpatient and outpatient services, partial hospitalization and outpatient prescription drugs for conditions that include cancer, end stage renal disease, hemophilia, hepatitis B and immunosuppressive drug therapy for people who received an organ or tissue transplant. These patients are often critically ill and their physicians have prescribed life-saving therapies.
As the voice for the life sciences industry in New Jersey, home to more than 50% of all new drug approvals in 2015, BioNJ strongly supports access to drugs for all patients. These proposed rule changes impact our country’s elderly and severely ill population. The changes are part of CMS’ effort to reduce healthcare costs. BioNJ supports responsible efforts to lower costs throughout our healthcare system, but they must be done in a way that allows physicians to treat their patients as they deem fit, and in a manner that will protect the most vulnerable patients.
BioNJ will work with New Jersey’s congressional delegation to lend their support to our request that CMS withdraw the proposed rule change.” CMS will be accepting comments on the proposed rule through May 9, 2016.
BioNJ, The Gateway to Health, is a powerful network of 400 Members representing research-based life sciences companies and stakeholders dedicated to propelling a vibrant ecosystem where Science is Supported, Companies are Created, Drugs are Developed and Patients are Paramount. Because Patients Can’t WaitSM, BioNJ supports its Members in the discovery, development and commercialization of therapies and cures that save and improve lives and lessen the burden of illness and disease to society by driving capital formation, fostering entrepreneurship, advocating for public policies that advance medical innovation, providing access to talent and education and offering a cost-saving array of critical commercial resources. For more information about BioNJ, please visit www.BioNJ.org.
Vice President, Communications and Marketing